ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2176

Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease

Nicholas C Chan1, Anika Rueppell2, Daniela Dominguez3, Tom Appleton4, Michelle Batthish5, Roberta A Berard6, Tania Cellucci5, Erkan Demirkaya7, Michelle Diebold6, Liane Heale8, Peter Kannu9, Deborah Levy10, Jonathan Park11, Jean-Philippe Proulx-Gauthier12, Angela Punnett10, Johannes Roth13, Rayfel Schneider14, Lynn Spiegel15, Rae Yeung16, Jason An1, Anjali Jain3, Madeline Couse10, Dilan Dissanayake10, Ronald Laxer2, Lauren Erdman10 and Linda Hiraki10, 1University of Toronto, Toronto, ON, Canada, 2SickKids, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4The University of Western Ontario, London, ON, Canada, 5McMaster Children's Hospital, Hamilton, ON, Canada, 6London Health Sciences Centre, London, ON, Canada, 7Victoria Hospital & Children's Hospital, Toronto, ON, Canada, 8McMaster University, Oakville, ON, Canada, 9University of Alberta, Edmonton, AB, Canada, 10The Hospital for Sick Children, Toronto, ON, Canada, 11London Health Sciences Centre Victoria Hospital, Lodon, Canada, 12l'Université Laval, Quebec City, QC, Canada, 13Cantonal Hospital Luzern and Children's Hospital of Central Switzerland, Luzern, Switzerland, 14The Hospital for Sick Children, Toronto, Ontario, Canada, Toronto, ON, Canada, 15University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 16The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic inflammatory diseases (SIDs) are characterized by non-infectious multisystem inflammation. Genetic panels only diagnose 25% of suspected SID patients, due to the clinical and genetic heterogeneity of SIDs. We hypothesize that integration of clinical and laboratory data will improve the diagnosis and evaluation of SIDs by creating shared biologically-based patient phenotypes. We aimed to identify patient clusters with shared clinical and laboratory features within a heterogeneous SID cohort, using similarity network fusion (SNF), a method for multifactorial data integration.

Methods: We included pediatric genetically undiagnosed SID patients with clinical, laboratory, and whole-exome sequencing data. Disease features were divided into clinical and laboratory data sets, weighted by missingness and the number of variables in each data set, then input into SNF. Fisher’s exact test (Bonferroni corrected P< 0.0004) identified variables with different distributions between clusters. We validated our model with 2 simulations (1000 simulated SNF each). Simulation 1: each iteration randomly re-distributed relevant variables into 2 simulated data sets, performed SNF and identified variables with different distributions between simulated clusters. Simulation 2: each iteration randomly subsampled 70% of our cohort into a simulated data set, performed SNF, and determined the percent of patients in the simulated data set that had identical clustering to our original clusters.

Results: Our study included 104 patients with undifferentiated SID (table 1). SNF revealed 2 clusters in our cohort. Cluster 1 (n=72) had a median age of symptom onset of 5.7 years and cluster 2 (n=32), 6 years. Cluster 2 included patients with more severe SID features compared to cluster 1. Specifically, elevated levels of IgG antibodies and the presence of hepatitis, anti-nuclear antibodies, anemia, and macrophage activation syndrome characterized cluster 2 and were normal/absent in cluster 1 (P< 1×10-7; figure 1). The majority of variables that differentiated the clusters were laboratory features. Simulation 1 demonstrated that the same features were consistently significant in defining clustering ( >946 times out of 1000). Simulation 2 illustrated that 95% of cluster 1 patients (69/72) and 82% of cluster 2 patients (26/32), consistently clustered together over 1000 SNF iterations.

Conclusion: SNF identified 2 relatively homogenous and robust patient clusters from a heterogeneous SID cohort. Simulations showed that 89% of the patients consistently clustered together and that laboratory variables primarily determined these clusters. Future work will incorporate genetic data into SNF to identify shared genetic and inflammatory pathways within clusters.

Supporting image 1

Supporting image 2

Figure 1. Clinical and Laboratory Features With Different Distribution Between SNF Clusters. Numeric values represent the prevalence of the feature within cluster 1 and 2. “+” represents the presence of the listed variable, “ANA” stands for anti-nuclear antibody and “MAS” stands for macrophage activation syndrome. Statistics performed with a Fishers Exact Test, Bonferroni corrected P<0.0004.


Disclosures: N. Chan: None; A. Rueppell: None; D. Dominguez: None; T. Appleton: AbbVie/Abbott, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, Servier, 5; M. Batthish: Abbvie, 6, Novartis, 2, Viatris, 12, Unrestricted Educational Grant; R. Berard: AbbVie/Abbott, 1, Sandoz, 1; T. Cellucci: None; E. Demirkaya: None; M. Diebold: None; L. Heale: Novartis, 5; P. Kannu: None; D. Levy: AbbVie, 5, AstraZeneca, 5, Roche, 5, SOBI, 5; J. Park: None; J. Proulx-Gauthier: None; A. Punnett: None; J. Roth: None; R. Schneider: None; L. Spiegel: None; R. Yeung: None; J. An: None; A. Jain: None; M. Couse: None; D. Dissanayake: None; R. Laxer: Akros pharma, 2, Eli Lilly canada, 2, Novartis, 2, Sanofi, 2, sobi, 2; L. Erdman: None; L. Hiraki: Janssen, 2.

To cite this abstract in AMA style:

Chan N, Rueppell A, Dominguez D, Appleton T, Batthish M, Berard R, Cellucci T, Demirkaya E, Diebold M, Heale L, Kannu P, Levy D, Park J, Proulx-Gauthier J, Punnett A, Roth J, Schneider R, Spiegel L, Yeung R, An J, Jain A, Couse M, Dissanayake D, Laxer R, Erdman L, Hiraki L. Applying Similarity Network Fusion to Identify Patient Clusters for People with Systemic Inflammatory Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/applying-similarity-network-fusion-to-identify-patient-clusters-for-people-with-systemic-inflammatory-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/applying-similarity-network-fusion-to-identify-patient-clusters-for-people-with-systemic-inflammatory-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology